Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. (OCUL) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · OCUL · as of Sep 30, 2025
Ownership Breakdown
229
Institutional Holders
▲ 33 vs Q2
$2.20B
Total Inst. Value
▲ $746.31M vs Q2
218.96M
Shares Outstanding
freeFloat 84.32%
188.18M
13F Shares Held
▲ 31.12M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
OCUL largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
FMR LLC pharmaceutical preparations | 31.79M | 18.42% | 18.42% | $371.57B | Nov 13, 2025 | ▲ 12.18M |
VR ADVISER, LLC pharmaceutical preparations | 13.16M | 7.63% | 7.63% | $153.86B | Nov 14, 2025 | ▲ 399.0K |
SUMMER ROAD LLC pharmaceutical preparations | 12.58M | 7.29% | 7.29% | $147.05B | Nov 7, 2025 | ▼ 1.31M |
DEEP TRACK CAPITAL, LP pharmaceutical preparations | 11.93M | 6.91% | 6.91% | $139.49B | Nov 14, 2025 | ▼ 2.36M |
BLACKROCK, INC. pharmaceutical preparations | 10.56M | 6.12% | 6.12% | $123.41B | Nov 12, 2025 | ▲ 10.5K |
AVORO CAPITAL ADVISORS LLC pharmaceutical preparations | 10.25M | 5.94% | 5.94% | $119.82B | Nov 14, 2025 | ▲ 2.85M |
VANGUARD GROUP INC pharmaceutical preparations | 9.16M | 5.31% | 5.31% | $107.12B | Nov 7, 2025 | ▲ 771.1K |
TCG CROSSOVER MANAGEMENT, LLC pharmaceutical preparations | 6.12M | 3.54% | 3.54% | $71.51B | Nov 17, 2025 | ▲ 798.1K |
CITADEL ADVISORS LLC pharmaceutical preparations | 5.70M | 3.30% | 3.30% | $66.68B | Nov 14, 2025 | ▲ 817.8K |
POINT72 ASSET MANAGEMENT, L.P. pharmaceutical preparations | 4.60M | 2.67% | 2.67% | $53.79B | Nov 14, 2025 | ▲ 2.70M |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
32
Increased
+36.69M shares4
New Positions
first time holders12
Decreased
−6.96M shares0
Sold Out
fully exitedNet shares change (top 50)
+29.73M
+36.69M / −6.96M
Net new holders
+24
4 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
OCUL insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
2
Buy transactions
7
Sell transactions
0.29
Buy/Sell ratio
$1M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Waheed Nadia Chief Medical Officer | Jun 3, 2026 | Sale | 14,828 | $8.27 | $122.6K | 300.1K | Form 4 ↗ |
Dugel Pravin See Remarks | May 26, 2026 | Sale | 21,156 | $8.20 | $173.5K | 2.60M | Form 4 ↗ |
Dugel Pravin See Remarks | May 28, 2026 | Gift | 394,696 | — | — | 694.8K | Form 4 ↗ |
Dugel Pravin See Remarks | May 28, 2026 | Gift | 394,696 | — | — | 0 | Form 4 ↗ |
Kaiser Peter Chief Development Officer | May 26, 2026 | Sale | 2,967 | $8.20 | $24.3K | 266.1K | Form 4 ↗ |
Heier Jeffrey S. Chief Scientific Officer | May 26, 2026 | Sale | 3,018 | $8.20 | $24.7K | 320.4K | Form 4 ↗ |
Nayak Sanjay Chief Strategy Officer | May 26, 2026 | Sale | 1,858 | $8.20 | $15.2K | 328.8K | Form 4 ↗ |
Dugel Pravin See Remarks | Apr 9, 2026 | Gift | 394,696 | — | — | 2.62M | Form 4 ↗ |
Dugel Pravin See Remarks | Apr 9, 2026 | Gift | 394,696 | — | — | 394.7K | Form 4 ↗ |
Dugel Pravin See Remarks | Feb 23, 2026 | Sale | 20,056 | $8.28 | $166.1K | 3.01M | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Ocular Therapeutix, Inc. (OCUL) is primarily owned by institutional investors, who hold approximately 85.9% of total shares outstanding. Company insiders own approximately 15.68%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Ocular Therapeutix, Inc. is FMR LLC, holding approximately 31.79 million shares — equal to 18.42% of outstanding shares — as of September 30, 2025.
A total of 229 institutional investors currently hold OCUL stock, with a combined institutional value of approximately $2.20 billion as of the most recent 13F filing period.
Frequently asked questions
OCUL ownershipOcular Therapeutix, Inc. (OCUL) is primarily owned by institutional investors, who hold approximately 85.9% of shares. The largest shareholder is FMR LLC with a 18.42% stake. Company insiders hold 15.68%. Data sourced from SEC Form 13F as of September 30, 2025.